Dec 2025 (Q4 FY25) — Feb 24, 2026
Vaxcyte Q4 FY25 — Advancing PCV Franchise with Key Clinical Milestones and Strengthened Financial Position
Read the full callVaxcyte (PCVX) earnings
- Jun 2026
- Dec 2025 (Q4 FY25)
- Dec 2025
Vaxcyte earnings: last reported Tue, 24 Feb 2026, for the quarter ended Dec 2025.
Reported
The figures, each with its period
Each figure keeps its basis and period; nothing is filled in.
| Metric | Value | Change | Basis | Period | Note |
|---|---|---|---|---|---|
| Revenue | Quarterly, as filed | Quarter to Jun 2026 | Not in the filed figures for the quarter to jun 2026. No older figure is substituted. | ||
| Operating margin | Operating profit / revenue | Quarter to Jun 2026 | Not in the filed figures for the quarter to jun 2026. No older figure is substituted. | ||
| Net profit | -284 | Quarterly, as filed | Quarter to Jun 2026 | Profit after tax as filed. The year-earlier figure was zero or a loss, so no percentage is shown. |
Price
$63.68 +0.09% · +$0.06
Performance +50.2% 1Y
1Y: $42.39 on 17 Oct 2025 → $63.68. High $73.82 (5 Oct 2026), low $40.32 (5 Nov 2025).
- Previous close
- $63.62
- 52-week range
- $40.32 – $73.82
- One year
- +48.44%
Overview
- Symbol
- PCVX
- Sector
- Health Care
- Exchange
- US
- Currency
- USD
Call summaries
Every analysed call
Vaxcyte earnings calls (PCVX)
Financials
What the filings say
Net profit, year on year: −71% (quarter to jun 2026 against jun 2025).
| Line item | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Operating profit | -140 | -162 | -181 | -226 | -242 | -274 | -346 | -303 |
| Other income | 37 | 25 | 40 | 60 | 30 | 28 | 25 | 18 |
| Net profit | -103 | -137 | -141 | -167 | -213 | -247 | -321 | -284 |
| EPS ($ per share) | -0.83 | — | -1.04 | -1.22 | -1.56 | — | -2.30 | -1.97 |
| Line item | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Equity capital | — | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Reserves | — | -109 | -199 | -299 | -522 | -924 | -1,388 | -2,155 |
| Total liabilities | — | 12 | 47 | 40 | 53 | 167 | 205 | 317 |
| Fixed assets | — | 3 | 3 | 8 | 10 | 80 | 198 | 257 |
| Investments | — | — | — | 177 | 97 | 683 | 1,359 | 1,387 |
| Total assets | — | 66 | 393 | 324 | 1,006 | 1,408 | 3,511 | 3,003 |
| Line item | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Cash from operations | -30 | -47 | -47 | -121 | -171 | -297 | -453 | -656 |
| Cash from investing | -2 | -1 | -1 | -212 | 75 | -773 | -2,006 | 437 |
| Cash from financing | 62 | 42 | 375 | 18 | 862 | 640 | 2,449 | 2 |
| Net cash flow | 30 | -7 | 327 | -316 | 766 | -437 | -9 | -214 |
| Capital expenditure | -2 | -1 | -1 | -7 | -6 | -16 | -22 | -14 |
| Free cash flow | -32 | -48 | -48 | -128 | -176 | -313 | -475 | -669 |
Insider filings
120 filings between Dec 23, 2025 and Oct 5, 2026.
Open market
decisions to buy or sellPurchases
None
No insider bought shares.
Sales
$12.42M
54 sales by 5 insiders
83% filed under a 10b5-1 plan — scheduled in advance, not decided on the day
Compensation
not trading decisions- 16
- Award — granted as compensation
- 15
- Option exercise — converted options into shares
- 31
- Tax withheld — shares kept back by the company to cover tax
Also filed: 4 gifts.
Who traded
open market only| Insider | Bought | Sold | Last filing |
|---|---|---|---|
| PICKERING GRANT | — | $3.63M | Jul 27, 2026 |
| Wassil Jim | — | $3.12M | Oct 5, 2026 |
| Cowan Elvia | — | $2.64M | Oct 5, 2026 |
| GUGGENHIME ANDREW | — | $1.64M | Aug 3, 2026 |
| Dhaliwal Harpreet S. | — | $1.39M | Aug 5, 2026 |
Latest filings (50)
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| Oct 5, 2026 | Cowan Elvia SVP, Finance & CAO | Option exercise 10b5-1 plan | 19,000 | $492.5K |
| Oct 5, 2026 | Cowan Elvia SVP, Finance & CAO | Sale 10b5-1 plan | 19,000 | $1.65M |
| Oct 5, 2026 | Wassil Jim EVP, Chief Scientific Ofc, COO | Option exercise 10b5-1 plan | 18,000 | $96.3K |
| Oct 5, 2026 | Wassil Jim EVP, Chief Scientific Ofc, COO | Sale 10b5-1 plan | 18,000 | $1.56M |
| Oct 1, 2026 | Wassil Jim EVP, Chief Scientific Ofc, COO | Sale 10b5-1 plan | 2,155 | $122.1K |
| Oct 1, 2026 | Wassil Jim EVP, Chief Scientific Ofc, COO | Sale 10b5-1 plan | 95 | $5.4K |
| Oct 1, 2026 | Wassil Jim EVP, Chief Scientific Ofc, COO | Option exercise 10b5-1 plan | 2,250 | $12.0K |
| Sep 9, 2026 | Wassil Jim EVP, Chief Scientific Ofc, COO | Sale | 1,334 | $79.4K |
| Sep 8, 2026 | GUGGENHIME ANDREW PRESIDENT AND CFO | Tax withheld | 7,155 | $431.9K |
| Sep 8, 2026 | PICKERING GRANT CHIEF EXECUTIVE OFFICER | Tax withheld | 17,056 | $1.03M |
| Sep 8, 2026 | Wassil Jim EVP, Chief Scientific Ofc, COO | Tax withheld | 5,459 | $329.5K |
| Sep 8, 2026 | Dhaliwal Harpreet S. Chief Technical Ops Officer | Tax withheld | 7,651 | $461.8K |
| Sep 8, 2026 | Cowan Elvia SVP, Finance & CAO | Tax withheld | 1,327 | $80.1K |
| Sep 4, 2026 | Jodar Luis Chief Medical Officer | Award | 52,632 | $0 |
| Sep 4, 2026 | Wassil Jim EVP, Chief Scientific Ofc, COO | Sale | 1,381 | $84.5K |
| Sep 2, 2026 | GUGGENHIME ANDREW PRESIDENT AND CFO | Tax withheld | 1,432 | $88.2K |
| Sep 2, 2026 | PICKERING GRANT CHIEF EXECUTIVE OFFICER | Tax withheld | 3,427 | $211.0K |
| Sep 2, 2026 | Wassil Jim CHIEF OPERATING OFFICER | Tax withheld | 1,432 | $88.2K |
| Sep 2, 2026 | Dhaliwal Harpreet S. Chief Technical Ops Officer | Tax withheld | 659 | $40.6K |
| Sep 2, 2026 | Cowan Elvia SVP, Finance & CAO | Tax withheld | 326 | $20.1K |
| Sep 1, 2026 | Wassil Jim CHIEF OPERATING OFFICER | Sale | 713 | $43.8K |
| Sep 1, 2026 | Wassil Jim CHIEF OPERATING OFFICER | Sale | 924 | $56.3K |
| Sep 1, 2026 | Wassil Jim CHIEF OPERATING OFFICER | Option exercise | 2,250 | $12.0K |
| Sep 1, 2026 | Wassil Jim CHIEF OPERATING OFFICER | Sale | 303 | $18.6K |
| Sep 1, 2026 | Wassil Jim CHIEF OPERATING OFFICER | Sale | 1,537 | $93.6K |
| Aug 31, 2026 | PICKERING GRANT CHIEF EXECUTIVE OFFICER | Tax withheld | 2,862 | $173.8K |
| Aug 31, 2026 | Wassil Jim CHIEF OPERATING OFFICER | Tax withheld | 1,273 | $77.3K |
| Aug 31, 2026 | Cowan Elvia SVP, Finance & CAO | Tax withheld | 243 | $14.8K |
| Aug 31, 2026 | Dhaliwal Harpreet S. Chief Technical Ops Officer | Tax withheld | 361 | $21.9K |
| Aug 31, 2026 | GUGGENHIME ANDREW PRESIDENT AND CFO | Tax withheld | 1,273 | $77.3K |
| Aug 5, 2026 | Dhaliwal Harpreet S. Chief Technical Ops Officer | Option exercise 10b5-1 plan | 17,000 | $421.4K |
| Aug 5, 2026 | Dhaliwal Harpreet S. Chief Technical Ops Officer | Sale 10b5-1 plan | 17,000 | $935.1K |
| Aug 3, 2026 | GUGGENHIME ANDREW PRESIDENT AND CFO | Sale 10b5-1 plan | 3,044 | $164.9K |
| Aug 3, 2026 | Wassil Jim CHIEF OPERATING OFFICER | Sale 10b5-1 plan | 1,389 | $75.1K |
| Aug 3, 2026 | GUGGENHIME ANDREW PRESIDENT AND CFO | Option exercise 10b5-1 plan | 10,000 | $53.5K |
| Aug 3, 2026 | Wassil Jim CHIEF OPERATING OFFICER | Sale 10b5-1 plan | 861 | $46.1K |
| Aug 3, 2026 | Wassil Jim CHIEF OPERATING OFFICER | Option exercise 10b5-1 plan | 2,250 | $12.0K |
| Aug 3, 2026 | GUGGENHIME ANDREW PRESIDENT AND CFO | Sale 10b5-1 plan | 6,956 | $374.0K |
| Jul 27, 2026 | PICKERING GRANT CHIEF EXECUTIVE OFFICER | Sale 10b5-1 plan | 378 | $21.1K |
| Jul 27, 2026 | PICKERING GRANT CHIEF EXECUTIVE OFFICER | Sale 10b5-1 plan | 622 | $34.5K |
| Jul 27, 2026 | PICKERING GRANT CHIEF EXECUTIVE OFFICER | Sale 10b5-1 plan | 244 | $13.7K |
| Jul 27, 2026 | PICKERING GRANT CHIEF EXECUTIVE OFFICER | Sale 10b5-1 plan | 756 | $42.0K |
| Jul 27, 2026 | PICKERING GRANT CHIEF EXECUTIVE OFFICER | Sale 10b5-1 plan | 4,415 | $246.9K |
| Jul 27, 2026 | PICKERING GRANT CHIEF EXECUTIVE OFFICER | Option exercise 10b5-1 plan | 16,198 | $32.9K |
| Jul 27, 2026 | PICKERING GRANT CHIEF EXECUTIVE OFFICER | Sale 10b5-1 plan | 11,783 | $654.1K |
| Jul 6, 2026 | GUGGENHIME ANDREW PRESIDENT AND CFO | Option exercise 10b5-1 plan | 10,000 | $53.5K |
| Jul 6, 2026 | GUGGENHIME ANDREW PRESIDENT AND CFO | Sale 10b5-1 plan | 2,087 | $120.6K |
| Jul 6, 2026 | GUGGENHIME ANDREW PRESIDENT AND CFO | Sale 10b5-1 plan | 7,913 | $452.3K |
| Jul 1, 2026 | Wassil Jim CHIEF OPERATING OFFICER | Sale 10b5-1 plan | 6 | $347 |
| Jul 1, 2026 | Wassil Jim CHIEF OPERATING OFFICER | Sale 10b5-1 plan | 456 | $26.2K |
Source: SEC Form 4 filings. Form 4 reports transactions, not the cap table — absence of filings says nothing about how much an insider owns, and a quiet window is not a signal.
Your own record
Start an Inve Case for Vaxcyte, Inc.
Free account. Everything above stays public.
Write why you follow Vaxcyte, Inc. and the condition you want checked. Inve compares your numeric conditions with available results and management guidance; your own conditions remain yours to review.
Keep reading